Jun. 16. 2022
Osaka, Japan – June 16, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with 11 strengths in the NHI (National Health Insurance) drug price list. Sawai’s product line now includes 329 compounds with 809 strengths.
The list of approved products
1. Febuxostat Tablets, OD Tablets
| Generic name | Febuxostat |
|---|---|
| Strengths | Tablets: 10mg, 20mg, 40mg OD Tablets: 10mg, 20mg |
| Brand products | Feburic® Tablets 10mg, 20mg, 40mg |
2. Aripiprazole Tablets, Oral Solution
| Generic name | Aripiprazole |
|---|---|
| Strengths | Tablets: 1mg Oral Solution: 1mg |
| Brand products | ABILIFY® tablets 1mg, ABILIFY®oral solution 0.1% |
3. Dasatinib Tablets
| Generic name | Dasatinib Hydrate |
|---|---|
| Strengths | Tablets: 20mg, 50mg |
| Brand products | SPRYCEL® Tablets 20mg, 50mg |
4. Azacitidine for Injection
| Generic name | Azacitidine |
|---|---|
| Strengths | Injection: 100mg |
| Brand products | Vidaza® for Injection 100mg |
5. Teriparatide Injection
| Generic name | Teriparatide Acetate |
|---|---|
| Strengths | Injection: 56.5μ |
| Brand products | Teribone® Injection 56.5μg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.